Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER

CBER Director Peter Marks says center will mobilize necessary resources to make sure these provisions are implemented; Marks also offered comments in opposition to 'right-to-try' legislation.

FDA entrance sign 2016

More from Cell & Gene Therapies

More from Advanced Technologies